ImmunityBio (NASDAQ:IBRX) Trading Down 17.4% on Insider Selling

ImmunityBio, Inc. (NASDAQ:IBRX)’s share price traded down 17.4% during trading on Wednesday after an insider sold shares in the company. The stock traded as low as $9.38 and last traded at $9.54. 79,731,023 shares changed hands during trading, an increase of 73% from the average session volume of 46,170,664 shares. The stock had previously closed at $11.55.

Specifically, Director Barry J. Simon sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $9.25, for a total value of $92,500.00. Following the transaction, the director directly owned 3,081,604 shares in the company, valued at approximately $28,504,837. This represents a 0.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Barry J. Simon sold 165,000 shares of the company’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $10.25, for a total value of $1,691,250.00. Following the transaction, the director owned 2,925,821 shares in the company, valued at $29,989,665.25. This trade represents a 5.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In other news, Director Christobel Selecky sold 25,000 shares of ImmunityBio stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $10.00, for a total value of $250,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Analyst Ratings Changes

Several equities analysts recently issued reports on IBRX shares. HC Wainwright increased their target price on ImmunityBio from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday. D. Boral Capital reissued a “buy” rating and set a $23.00 price target on shares of ImmunityBio in a research report on Monday. Jefferies Financial Group lifted their price objective on shares of ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a report on Friday, December 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of ImmunityBio in a report on Monday, December 29th. Finally, Piper Sandler raised their price target on shares of ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $12.60.

Trending Headlines about ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Company reports massive ANKTIVA‑driven revenue surge (reported ~700% y/y / 5x growth), which investors view as confirmation commercial sales are ramping. ImmunityBio (IBRX) Reports 700% Revenue Surge
• Positive Sentiment: Q4 results beat expectations — EPS loss narrower than consensus and revenue well ahead, supporting the thesis that ANKTIVA commercialization is scaling. ImmunityBio Supersedes Expectations With Fivefold Revenue Increase
• Positive Sentiment: Regulatory/approval expansions and new commercial partnerships for ANKTIVA broaden the market opportunity and support upside to sales forecasts. ImmunityBio’s ANKTIVA Approvals Broaden Global Reach And Investor Opportunity
• Positive Sentiment: Several brokerages have reiterated buys and raised long‑term price targets (D. Boral Capital, HC Wainwright, Piper Sandler, BTIG), which helps sentiment and supports further upside if execution continues. ImmunityBio Earns Buy Rating from D. Boral Capital
• Neutral Sentiment: Commentary notes a disconnect between recent clinical progress/long‑term prospects and the stock’s short‑term volatility — useful context for traders but not an immediate earnings driver. ImmunityBio: Disconnect Between Clinical Progress And Stock Performance
• Neutral Sentiment: HC Wainwright adjusted near‑term EPS down modestly while materially raising FY2028–FY2030 estimates — implies near‑term profitability pressure but stronger long‑term optionality if commercialization scales. HC Wainwright Research Notes on IBRX Estimates
• Negative Sentiment: Insider selling: multiple director sales disclosed (large block sales by Chairman/directors), which can sap investor confidence even if not unusual for sizable holders. Director Barry Simon Sells Shares
• Negative Sentiment: Company remains unprofitable with a negative consensus for the current year — valuation and execution risk remain material despite revenue growth. ImmunityBio Q4 Press Release

ImmunityBio Trading Down 17.4%

The firm’s fifty day simple moving average is $4.82 and its 200 day simple moving average is $3.24. The company has a market cap of $9.40 billion, a price-to-earnings ratio of -25.11 and a beta of 0.14.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings data on Monday, March 2nd. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.02. The firm had revenue of $38.29 million for the quarter. As a group, sell-side analysts expect that ImmunityBio, Inc. will post -0.92 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Slow Capital Inc. acquired a new stake in shares of ImmunityBio in the third quarter valued at approximately $25,000. Envision Financial Planning LLC acquired a new stake in ImmunityBio during the 2nd quarter worth $28,000. Summit X LLC purchased a new position in ImmunityBio during the 2nd quarter worth $28,000. Diversify Advisory Services LLC purchased a new position in ImmunityBio during the 2nd quarter worth $27,000. Finally, Truist Financial Corp acquired a new position in ImmunityBio in the third quarter valued at $27,000. 8.58% of the stock is owned by institutional investors and hedge funds.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.